Literature DB >> 7751625

T cell development in insulin-like growth factor-II transgenic mice.

R Kooijman1, S C van Buul-Offers, L E Scholtens, H J Schuurman, L J Van den Brande, B J Zegers.   

Abstract

Growth hormone and insulin-like growth factor-I (IGF-I) have been demonstrated to play a role in T and B cell development. We studied the effects of IGF-II on T cell development in two transgenic mouse lines that overexpress human IGF-II under the control of the H2Kb promoter. The thymuses of 1-wk-old mice of two transgenic lines (5'-35 and 5'-74) contained 36 and 68%, respectively, more thymocytes than controls. Between 1 and 4 wk of age, the overexpression of IGF-II also resulted in a 2 to 2.5 times stronger increase in thymic cellularity. As in control mice, the number of thymocytes declined after 4 wk of age, and at 15 wk it was no longer significantly different from controls. Flowcytometric analysis indicated that at 2 and 4 wk of age, the increased thymic cellularity was associated with an increased number of early (CD4- CD8- or CD4- CD8dim), intermediate (CD4+CD8+), and mature thymocytes (CD3++CD4+CD8- or CD3++CD4-CD8+). However, the increase in the number of CD4+CD8- thymocytes was larger than the increase in the number of CD4-CD8+ thymocytes. As a consequence, CD4+ T cells mainly contributed to the increase in the number of T cells in spleen. These T cells showed a mature phenotype since they expressed CD3 and were negative for heat-stable antigen, a marker for immature T cells. These data indicate that overexpression of IGF-II increases thymic cellularity and stimulates the generation of phenotypically normal T cells with a preference to CD4+ cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751625

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Identification of cation-independent mannose 6-phosphate receptor/insulin-like growth factor type-2 receptor as a novel target of autoantibodies.

Authors:  D Tarrago; I Aguilera; J Melero; I Wichmann; A Nuñez-Roldan; B Sanchez
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

Review 2.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 3.  Emerging strategies to boost thymic function.

Authors:  Georg A Holländer; Werner Krenger; Bruce R Blazar
Journal:  Curr Opin Pharmacol       Date:  2010-05-04       Impact factor: 5.547

Review 4.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

Review 5.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

6.  Activation-dependent expression of the insulin-like growth factor binding protein-2 in human lymphocytes.

Authors:  J L Föll; L Dannecker; C Zehrer; S Hettmer; J Berger; M Elmlinger; D Niethammer; M B Ranke; G E Dannecker
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

7.  Resistance to age-dependent thymic atrophy in long-lived mice that are deficient in pregnancy-associated plasma protein A.

Authors:  Abbe N Vallejo; Joshua J Michel; Laurie K Bale; Bonnie H Lemster; Lisa Borghesi; Cheryl A Conover
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

8.  Insulin-Like Growth Factors Are Key Regulators of T Helper 17 Regulatory T Cell Balance in Autoimmunity.

Authors:  Daniel DiToro; Stacey N Harbour; Jennifer K Bando; Gloria Benavides; Steven Witte; Vincent A Laufer; Carson Moseley; Jeffery R Singer; Blake Frey; Henrietta Turner; Jens Bruning; Victor Darley-Usmar; Min Gao; Cheryl Conover; Robin D Hatton; Stuart Frank; Marco Colonna; Casey T Weaver
Journal:  Immunity       Date:  2020-04-14       Impact factor: 31.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.